成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. PI3K/Akt/mTOR Autophagy Apoptosis
  2. Akt Autophagy Apoptosis
  3. Perifosine

Perifosine  (Synonyms: 哌立福新; KRX-0401; NSC 639966; D21266)

目錄號: HY-50909 純度: 99.91%
COA 產(chǎn)品使用指南 技術(shù)支持

Perifosine是一種有口服活性的 Akt 抑制劑,抑制不同腫瘤細胞系增殖的 IC50 值為0.6-8.9 μM。

MCE 的所有產(chǎn)品僅用作科學研究或藥證申報,我們不為任何個人用途提供產(chǎn)品和服務

Perifosine Chemical Structure

Perifosine Chemical Structure

CAS No. : 157716-52-4

1.  客戶無需承擔相應的運輸費用。

2.  同一機構(gòu)(單位)同一產(chǎn)品試用裝僅限申領(lǐng)一次,同一機構(gòu)(單位)一年內(nèi)

     可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in Water ¥1191
In-stock
1 mg ¥461
In-stock
5 mg ¥1083
In-stock
10 mg ¥1989
In-stock
25 mg ¥3280
In-stock
50 mg ¥4906
In-stock
100 mg 現(xiàn)貨 詢價
200 mg   詢價  
500 mg   詢價  

* Please select Quantity before adding items.

Customer Review

    Perifosine purchased from MCE. Usage Cited in: Front Oncol. 2021 Apr 12;11:608570.  [Abstract]

    The rescue test of PI3K/Akt/mTOR signaling in response to 17α-PG in MDA-MB-453/BCRP cells. The cells are starved for 48 h and then treated with 1,000 nM 17α-PG combined with siAkt or Perifosine.

    查看 Akt 亞型特異性產(chǎn)品:

    • 生物活性

    • 實驗參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻

    生物活性

    Perifosine is an oral Akt inhibitor which inhibits proliferation of different tumor cell lines with IC50s of 0.6-8.9 μM.

    IC50 & Target[1]

    Autophagy

     

    細胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A549 IC50
    4.17 μM
    Compound: perifosine
    Cytotoxicity against human A549 cells after 24 to 72 hrs by haemocytometry
    Cytotoxicity against human A549 cells after 24 to 72 hrs by haemocytometry
    [PMID: 24900620]
    A549 IC50
    5.3 μM
    Compound: 2, OPP
    Inhibition of Akt phosphorylation in insulin-stimulated human A549 cells treated 2 hrs before insulin stimulation measured after 30 mins by ELISA
    Inhibition of Akt phosphorylation in insulin-stimulated human A549 cells treated 2 hrs before insulin stimulation measured after 30 mins by ELISA
    [PMID: 22138309]
    A549 IC50
    5.3 μM
    Compound: 2, OPP
    Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA
    Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA
    [PMID: 23415083]
    A549 IC50
    7 μM
    Compound: 2, OPP
    Cytotoxicity against human A549 cells after 24 hrs by FACS analysis
    Cytotoxicity against human A549 cells after 24 hrs by FACS analysis
    [PMID: 22138309]
    A549 IC50
    7 μM
    Compound: 2, OPP
    Cytotoxicity against human A549 cells by flow cytometric analysis
    Cytotoxicity against human A549 cells by flow cytometric analysis
    [PMID: 23415083]
    ACHN GI50
    4.56 μM
    Compound: Perifosine
    Growth inhibition of human ACHN cells after 48 hrs by SRB assay
    Growth inhibition of human ACHN cells after 48 hrs by SRB assay
    [PMID: 24095759]
    ACHN GI50
    4.56 μM
    Compound: Perifosine
    Antiproliferative activity against human ACHN cells by SRB assay
    Antiproliferative activity against human ACHN cells by SRB assay
    [PMID: 23567950]
    ACHN GI50
    4.56 μM
    Compound: Perifosine
    Growth inhibition of human ACHN cells by SRB assay
    Growth inhibition of human ACHN cells by SRB assay
    [PMID: 23266181]
    ACHN GI50
    4.56 μM
    Compound: Perifosine
    Growth inhibition of human ACHN cells by sulforhodamine B assay
    Growth inhibition of human ACHN cells by sulforhodamine B assay
    [PMID: 21543141]
    HCT-15 GI50
    1.25 μM
    Compound: Perifosine
    Growth inhibition of human HCT15 cells after 48 hrs by SRB assay
    Growth inhibition of human HCT15 cells after 48 hrs by SRB assay
    [PMID: 24095759]
    HCT-15 GI50
    1.25 μM
    Compound: Perifosine
    Antiproliferative activity against human HCT15 cells by SRB assay
    Antiproliferative activity against human HCT15 cells by SRB assay
    [PMID: 23567950]
    HCT-15 GI50
    1.25 μM
    Compound: Perifosine
    Growth inhibition of human HCT15 cells by SRB assay
    Growth inhibition of human HCT15 cells by SRB assay
    [PMID: 23266181]
    HCT-15 GI50
    1.25 μM
    Compound: Perifosine
    Growth inhibition of human HCT15 cells by sulforhodamine B assay
    Growth inhibition of human HCT15 cells by sulforhodamine B assay
    [PMID: 21543141]
    MCF7 IC50
    13.3 μM
    Compound: 2, OPP
    Cytotoxicity against human MCF7 cells after 24 hrs by FACS analysis
    Cytotoxicity against human MCF7 cells after 24 hrs by FACS analysis
    [PMID: 22138309]
    MCF7 IC50
    13.3 μM
    Compound: 2, OPP
    Cytotoxicity against human MCF7 cells by flow cytometric analysis
    Cytotoxicity against human MCF7 cells by flow cytometric analysis
    [PMID: 23415083]
    MDA-MB-231 GI50
    2.86 μM
    Compound: Perifosine
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay
    [PMID: 24095759]
    MDA-MB-231 GI50
    2.86 μM
    Compound: Perifosine
    Antiproliferative activity against human MDA-MB-231 cells by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells by SRB assay
    [PMID: 23567950]
    MDA-MB-231 GI50
    2.86 μM
    Compound: Perifosine
    Growth inhibition of human MDA-MB-231 cells by SRB assay
    Growth inhibition of human MDA-MB-231 cells by SRB assay
    [PMID: 23266181]
    MDA-MB-231 GI50
    2.86 μM
    Compound: Perifosine
    Growth inhibition of human MDA-MB-231 cells by sulforhodamine B assay
    Growth inhibition of human MDA-MB-231 cells by sulforhodamine B assay
    [PMID: 21543141]
    NCI-H23 GI50
    4.21 μM
    Compound: Perifosine
    Growth inhibition of human NCI-H23 cells after 48 hrs by SRB assay
    Growth inhibition of human NCI-H23 cells after 48 hrs by SRB assay
    [PMID: 24095759]
    NCI-H23 GI50
    4.21 μM
    Compound: Perifosine
    Antiproliferative activity against human NCI-H23 cells by SRB assay
    Antiproliferative activity against human NCI-H23 cells by SRB assay
    [PMID: 23567950]
    NCI-H23 GI50
    4.21 μM
    Compound: Perifosine
    Growth inhibition of human NCI-H23 cells by SRB assay
    Growth inhibition of human NCI-H23 cells by SRB assay
    [PMID: 23266181]
    NCI-H23 GI50
    4.21 μM
    Compound: Perifosine
    Growth inhibition of human NCI-H23 cells by sulforhodamine B assay
    Growth inhibition of human NCI-H23 cells by sulforhodamine B assay
    [PMID: 21543141]
    NUGC-3 GI50
    0.54 μM
    Compound: Perifosine
    Growth inhibition of human NUGC3 cells after 48 hrs by SRB assay
    Growth inhibition of human NUGC3 cells after 48 hrs by SRB assay
    [PMID: 24095759]
    NUGC-3 GI50
    0.54 μM
    Compound: Perifosine
    Antiproliferative activity against human NUGC3 cells by SRB assay
    Antiproliferative activity against human NUGC3 cells by SRB assay
    [PMID: 23567950]
    NUGC-3 GI50
    0.54 μM
    Compound: Perifosine
    Growth inhibition of human NUGC3 cells by SRB assay
    Growth inhibition of human NUGC3 cells by SRB assay
    [PMID: 23266181]
    NUGC-3 GI50
    0.54 μM
    Compound: Perifosine
    Growth inhibition of human NUGC3 cells by sulforhodamine B assay
    Growth inhibition of human NUGC3 cells by sulforhodamine B assay
    [PMID: 21543141]
    PC-3 GI50
    0.44 μM
    Compound: Perifosine
    Growth inhibition of human PC3 cells after 48 hrs by SRB assay
    Growth inhibition of human PC3 cells after 48 hrs by SRB assay
    [PMID: 24095759]
    PC-3 GI50
    0.44 μM
    Compound: Perifosine
    Antiproliferative activity against human PC3 cells by SRB assay
    Antiproliferative activity against human PC3 cells by SRB assay
    [PMID: 23567950]
    PC-3 GI50
    0.44 μM
    Compound: Perifosine
    Growth inhibition of human PC3 cells by SRB assay
    Growth inhibition of human PC3 cells by SRB assay
    [PMID: 23266181]
    PC-3 GI50
    0.44 μM
    Compound: Perifosine
    Growth inhibition of human PC3 cells by sulforhodamine B assay
    Growth inhibition of human PC3 cells by sulforhodamine B assay
    [PMID: 21543141]
    體外研究
    (In Vitro)

    MTT 法測定 Ntv-a/LacZ 細胞系生長的 IC50。當細胞在添加 10% FCS 的培養(yǎng)基中培養(yǎng) 48 小時時,具有組成型活性 PDGF、Ras 或 Akt 信號轉(zhuǎn)導的細胞的 IC50 相似,約為 45 μM[1]。Perifosine,一種口服生物可利用的烷基磷脂 (ALK),對永生化角質(zhì)形成細胞 (HaCaT) 以及頭頸部鱗狀癌細胞的細胞周期動力學的影響。通過將[3H]胸苷摻入細胞 DNA 來評估增殖。暴露于 Perifosine (0.1-30 μM) 24 小時會導致所有測試細胞系中[3H]胸苷攝取的劑量依賴性抑制。生長的 IC50 介于 0.6 和 8.9 μM 之間,達到 IC80 ~10 μM。Perifosine 通過誘導 p21WAF1 在 G1-S 和 G2-M 阻斷頭頸部鱗癌細胞的細胞周期進程,無論 p53 功能,并且可以在臨床上加以利用,因為大多數(shù)人類惡性腫瘤都存在 p53 突變。Perifosine (20 μM) 誘導 G1-S 和 G2-M 細胞周期停滯,以及 和 p21WAF1 表達>p53 野生型和 p53-/- 克隆[2]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    體內(nèi)研究
    (In Vivo)

    通過生物發(fā)光成像鑒定小鼠患有腫瘤,并用 100 mg/kg Temozolomide 或 30 mg/kg Perifosine 或 100 mg/kg Temozolomide 和 30 mg/kg Perifosine 的組合 (Temozolomide +Perifosine) 處理 3 至 5 天。處死小鼠并通過 Ki-67 免疫染色對腫瘤進行組織學細胞增殖分析。用 Temozolomide (Ki-67 染色指數(shù)=5.5±1.2%,n=4,P=0.0019) 或 Perifosine (Ki-67 染色指數(shù)=3.2±1.1%,n= 3,P=0.001) 與 Control 相比,顯示出對增殖的抑制作用。最重要的是,用 Temozolomide+ Perifosine 處理的腫瘤具有最低的 Ki-67 染色指數(shù) (1.7±1.2%,n=3,P=0.0005)。Perifosine 的額外處理導致增殖率顯著低于單獨的替莫唑胺 (P=0.0087)[1]。Perifosine 在注射后 10 分鐘至 24 小時顯著降低 p-Akt,隨后在注射后 1 小時至 24 小時適度降低 p-S6[3]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    分子量

    461.66

    Formula

    C25H52NO4P

    CAS 號
    性狀

    固體

    顏色

    White to off-white

    中文名稱

    哌立福新;派立福新

    運輸條件

    Room temperature in continental US; may vary elsewhere.

    儲存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性數(shù)據(jù)
    細胞實驗: 

    H2O 中的溶解度 : 100 mg/mL (216.61 mM; 超聲助溶)

    DMF 中的溶解度 : < 1 mg/mL (insoluble)

    DMSO 中的溶解度 : < 1 mg/mL (insoluble or slightly soluble)

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 2.1661 mL 10.8305 mL 21.6610 mL
    5 mM 0.4332 mL 2.1661 mL 4.3322 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C儲存時,請在6個月內(nèi)使用,-20°C儲存時,請在1個月內(nèi)使用。

    * 備注:如您選擇水作為儲備液,請稀釋至工作液后,再用 0.22 μm 的濾膜過濾除菌后使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實驗:

    以下溶解方案,請直接配制工作液。建議現(xiàn)用現(xiàn)配,在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比; 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的方式助溶。

    • 方案 一

      請依序添加每種溶劑: PBS

      Solubility: 50 mg/mL (108.30 mM); 澄清溶液; 超聲助溶

    動物溶解方案計算器
    請輸入動物實驗的基本信息:

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    由于實驗過程有損耗,建議您多配一只動物的量
    計算結(jié)果
    工作液所需濃度 : mg/mL
    該產(chǎn)品水溶性佳,請具體參考實測 水 / PBS / Saline 中的溶解度數(shù)據(jù)。
    您所需的儲備液濃度超過該產(chǎn)品的實測溶解度,如有需要,請與 MCE 中國技術(shù)支持聯(lián)系。
    純度 & 產(chǎn)品資料

    純度: 99.91%

    參考文獻
    Kinase Assay
    [2]

    Exponentially growing cells (HN12, HN30, and HaCaT) are lysed, and 500 μg of total cellular protein are used to immunoprecipitate active cdc2 and cdk2 complexes. After capturing with gammabind G Sepharose and subsequent washes, the active immune complexes are assessed for activity in the presence of increasing concentrations of Perifosine (0.1-30 μM) or flavopiridol (300 nM) in the kinase assay buffer containing [γ-32P]ATP (3000 Ci/mmol) and 0.2 mg/mL histone H1, 25 μM ATP. Reactions are incubated at 37°C for 30 min and terminated by the addition of SDS-gel loading buffer, resolved in SDS-PAGE, and dried gels are subjected to autoradiography and phosphorimaging[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [2]

    Cell proliferation studies by measuring the uptake of [3H]thymidine is performed. Briefly, HNSCC and HaCaT cells (1-2×104/well) are grown overnight in 24-well plates and exposed to either Perifosine (0.1-30 μM) or PBS (control). After treatment (24-48 h), cells are pulsed with [3H]thymidine (1 μCi/well) for 4-6 h, fixed (5% trichloroacetic acid), and solubilized (0.5 M NaOH) before scintillation counting. Experiments are performed in triplicates[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1][3]

    Mice[1]
    Drug treatment of tumor-bearing mice. Image-positive Ef-luc Ntv-a mice are treated daily with i.p. administration of buffer alone as a control, or i.p. administration of 100 mg/kg Temozolomide, or oral administration of 30 mg/kg Perifosine, or a combination with Perifosine and Temozolomide for 3 to 5 days. The mean doses of the treatments are: Control, 5 (all five); Temozolomide, 3.75 (three to five); Perifosine, 3.75 (three to four); and Perifosine+Temozolomide, 3 (all three). Control buffer solution consisted of 5% DMSO and 1% Tween 80 in distilled water.
    Rats[3]
    To further determine whether the paradoxical effect of rapamycin on S6 phosphorylation is related to upstream signals of Akt-mTOR, rats are treated with Perifosine (20 mg/kg, ip, once), an Akt inhibitor, 30 min before rapamycin administration. Rats are sacrificed 1 h or 6 h after rapamycin injection.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    參考文獻

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C儲存時,請在6個月內(nèi)使用,-20°C儲存時,請在1個月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    H2O 1 mM 2.1661 mL 10.8305 mL 21.6610 mL 54.1524 mL
    5 mM 0.4332 mL 2.1661 mL 4.3322 mL 10.8305 mL
    10 mM 0.2166 mL 1.0830 mL 2.1661 mL 5.4152 mL
    15 mM 0.1444 mL 0.7220 mL 1.4441 mL 3.6102 mL
    20 mM 0.1083 mL 0.5415 mL 1.0830 mL 2.7076 mL
    25 mM 0.0866 mL 0.4332 mL 0.8664 mL 2.1661 mL
    30 mM 0.0722 mL 0.3610 mL 0.7220 mL 1.8051 mL
    40 mM 0.0542 mL 0.2708 mL 0.5415 mL 1.3538 mL
    50 mM 0.0433 mL 0.2166 mL 0.4332 mL 1.0830 mL
    60 mM 0.0361 mL 0.1805 mL 0.3610 mL 0.9025 mL
    80 mM 0.0271 mL 0.1354 mL 0.2708 mL 0.6769 mL
    100 mM 0.0217 mL 0.1083 mL 0.2166 mL 0.5415 mL

    * 備注:如您選擇水作為儲備液,請稀釋至工作液后,再用 0.22 μm 的濾膜過濾除菌后使用。

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱:

     

    * 需求量:

    * 客戶姓名:

     

    * Email:

    * 電話:

     

    * 公司或機構(gòu)名稱:

       留言給我們:

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱:
    Perifosine
    目錄號:
    HY-50909
    需求量: